JOHN P. MCKEARN, Ph.D.
Chief Executive Officer and President
Dr. McKearn is also on the boards of Allakos, OncoResponse, Good Therapeutics, Arch Oncology and Adarza Biosystems. He previously served on the boards of IDM Pharma (acquired by Takeda), Epimmune, Kalypsys, Keel Pharmaceuticals, Lumena Pharmaceuticals (acquired by Shire), Otonomy and ZS Pharma (acquired by Astra Zeneca). Dr. McKearn has co-authored more than 70 published, peer-reviewed scientific papers, and holds more than 50 patents and numerous patent applications, primarily in the areas of cancer treatment and inflammatory disease.
Dr. McKearn holds a Ph.D. in Immunology from the University of Chicago and a Bachelor of Science in Biology from Northern Illinois University.
MATTHEW COOPER, Ph.D.
Founder and Chief Scientific Officer
Dr. Cooper holds a Ph.D. in Cancer Genetics from the University of Surrey, Guildford, UK.
KENNETH CHROBAK, Ph.D.
VICE PRESIDENT, PRODUCT DEVELOPMENT
Dr. Chrobak received his Ph.D. in biomedical engineering from Boston University and his Bachelor of Science in chemical engineering from the University of Illinois at Urbana-Champaign.
KAREN GHEESLING MULLIS, Ph.D.
Vice President, R&D Project management
Dr. Gheesling Mullis has over 20 years of drug discovery, drug development, and investing experience in global pharmaceutical and drug biotech. Prior to joining Wugen, Dr Gheesling Mullis was President of RiverVest’s Archer Seed Venture Partners, L.L.C., investing in early stage biopharma companies. From 1995-2016, Dr. Gheesling Mullis held increasingly responsible positions in research and development at Pfizer and heritage companies Searle/Pharmacia. She was an asset project manager in early and late clinical development programs from IND submissions through global submissions and new drug approvals, including IBRANCEⓇ (palbociclib) for mBC and XALKORI Ⓡ (Crizotinib) ROS1 + NSCLC.
Dr. Gheesling Mullis holds a Ph.D. in Biochemistry at University of Alabama, Birmingham followed by a postdoctoral fellowship at Washington University, St. Louis in glycobiology. She also holds a Bachelor of Science in Chemistry from Emory University.
MARY CELINE SCOTT, Ph.D., MBA
Vice President, Regulatory Affairs
Dr. Scott received a Ph.D. from Purdue University in Pharmacology (specialization neuroscience), followed by a postdoctoral fellowship at the Mayo Clinic in the emerging field of pharmacogenetics. She also holds an MBA in Pharmaceutical/Chemical Studies from Fairleigh-Dickinson University, an MS in Biology from California State University, Long Beach and a BS in Biological Sciences from the University of California, Irvine.
AYMAN KABAKIBI, Ph.D.
Vice President, Research and development
Dr. Kabakibi received his Ph.D. in biochemistry from the University of Massachusetts Lowell and his Master of Science in medical laboratory sciences from Northeastern University.
MARK LEWIS, Ph.D.
Vice President, finance and business operations
Dr. Lewis received his Ph.D. in molecular biology and Master of Art in biology from Washington University in Saint Louis and his Bachelor of Science in biochemistry from Eastern Connecticut State University.